Business Wire

Altan Pharma Submits New Drug Application for Acetaminophen Solution for Infusion for Treatment of Pain and Reduction of Fever

Del

Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company, today announces that it has submitted a New Drug Application (NDA) for its formulation of acetaminophen solution for infusion to the United States Food and Drug Administration (FDA) and that it has been accepted for review. The NDA was submitted pursuant to section 505(b)(2) of the Food, Drug and Cosmetic Act.

Acetaminophen Solution for Infusion is an analgesic used to treat mild to moderate pain in adult and pediatric patients two years and older, moderate to severe pain in conjunction with adjunctive opioid analgesics in the same population and for the reduction of fever in adult and pediatric patients.

Traditional intravenous formulations of acetaminophen are extremely sensitive to oxygen, requiring them to be deoxygenated in the manufacturing process and to be packaged in glass vials to maintain stability throughout their approved shelf life. Altan has developed a unique, ready-to-use formulation that does not require deoxygenation and that can be packaged in flexible plastic containers, which are preferred by hospitals.

Altan announced last April that the United States Patent and Trademark Office (“USPTO”) had awarded the Company two patents covering its unique formulation of intravenous acetaminophen. These patents will provide protection for Altan’s intravenous formulation of acetaminophen until July 18, 2026. In addition to the US patents, Altan holds patents on its formulation of intravenous acetaminophen in Canada, Japan, Australia, South Africa, France, Germany, Spain, Italy, and the UK as well as most other European countries. Altan has manufactured and sold more than 200 million units of its intravenous acetaminophen formulation in the above non-US markets.

According to IMS, the US market for intravenous acetaminophen is around 10 million units, or $300 million annually. The US market is currently dominated by one supplier that holds a patent on the process for deoxygenating intravenous formulations. By contrast, Altan’s process for producing Acetaminophen for infusion does not require deoxygenation and therefore offers the potential for an alternative solution in the US market.

Guillermo Herrera, CEO of Altan said: “We are delighted that the FDA has accepted our registration package for review. If marketed, our product has the potential to offer a superior, more economically favorable solution for hospitals, patients and payors”.

About Altan Pharma Ltd.

Altan Pharma Ltd. is a privately held, specialty pharmaceutical company that develops, manufactures and commercializes injectable drugs for the hospital and other provider segments. Altan has a broad geographic footprint covering many European, Latin American and Asian markets. The company is highly focused on building its pipeline of injectable drugs and expanding its commercial presence to new markets, including the United States, through both organic and inorganic means. Altan’s Lead Investors are Malin Corporation plc (Euronext Dublin: MLC) and Lake Forest Pharma Investments, LLC.

Forward Looking Statements

This press release contains “forward-looking statements” subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including the difficulty of predicting FDA approvals, acceptance and demand for pharmaceutical products, the impact of competitive products and pricing, new product development and launch, the regulatory environment, etc. This press release is made only as of the date hereof, and unless otherwise required by applicable securities laws, Altan disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information visit www.altanpharma.com

Contact information

Altan Media Relations Contact
Mark Gorman
Tel: + 353 1 908 1280
Email: info@altanpharma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

New Enforce Tac Exhibitor Meggitt Training Systems to Exhibit Portable, Small-Arms Simulator19.2.2019 09:00:00Pressemelding

Meggitt Training Systems will conduct demonstrations of its FATS® 100P portable simulator during its first visit to Enforce Tac (stand 12-129) on March 6-7, 2019, in Nuremberg, Germany. Leveraging key features from the US Army Engagement Skills Trainer II and US Marine Corps Indoor Simulated Marksmanship Trainer programs of record, the industry-leading FATS 100P delivers a significant expansion in virtual small-arms training capability and is ideally suited for use by European law enforcement departments. “As tactical law enforcement challenges evolve, Meggitt is leveraging in-house expertise and customer feedback to expand its line of simulators from the immersive FATS 300 and 180 to the portable 100P,” said Matt Cunningham, Meggitt’s director of virtual systems sales. “Enforce Tac visitors to our stand can learn more, especially how the FATS 100P facilitates training resource sharing among units, as well as enables field deployment for easy set-up in a room that’s not a dedicated tra

ABB Wins $42 Million Order for Train Technologies from Indian Railways19.2.2019 08:30:00Pressemelding

ABB has won its largest traction equipment order in India, worth more than $42 million to supply state-of-the-art converters for electric locomotives from Diesel Locomotive Works (DLW), in Varanasi. The converters are custom designed for Indian Railways and will be manufactured at one of ABB’s largest factories for locomotive applications in Nelamangala, near Bengaluru, in Southern India. ABB’s traction solution is based on the latest technology to bring more reliable trains to passengers, while increasing sustainable transport use by moving from diesel trains to electric. This helps rail operators to achieve significant operational improvements. “We are delighted to be contributing to the electrification of India’s rail network with ABB’s locally manufactured solutions,” said ABB CEO Ulrich Spiesshofer. “By adopting advanced technologies, India is achieving rapid improvements in growth and productivity and shaping its economy for the era of digitalization.” “We are privileged to work

Exclusive Group Further Advances Global VAD Reach with Acquisition of SecureWave in Israel19.2.2019 08:06:00Pressemelding

Exclusive Group, the value-added services and technologies (VAST) group, today announced it is acquiring SecureWave, one of Israel’s leading independent cybersecurity VADs. The move adds another advanced economy to the worldwide market penetration of the Exclusive Group, establishes an in-country presence within one of the world’s most significant innovation hubs, and expands the Group’s service reach to the benefit of its global customers and partners. “This acquisition is about more than just filling in the gaps of our EMEA footprint – it represents a fantastic opportunity to tap into a significant new local market and use our in-country presence to extend relationships with Israeli-based technology innovators,” said Olivier Breittmayer, CEO at Exclusive Group. “In SecureWave we feel we have identified a like-minded VAD business with a committed and successful team who understand value. And as well as similar business principles, we also share some of the same cybersecurity and cloud

The O-RAN Alliance Announces New Open Fronthaul Specification, Demos and Industry Event at Mobile World Congress 201919.2.2019 08:00:00Pressemelding

The O-RAN Alliance announced today that it will be releasing the first O-RAN standard Open Fronthaul Specifications comprised of control, user, synchronization and management plane protocols. Sachin Katti, Stanford University Professor and O-RAN TSC co-chair said, “we are excited to release the first O-RAN Open Fronthaul Specification. O-RAN has leveraged significant specification work done in xRAN and will accelerate interoperability testing and product commercialization. Further, the O-RAN fronthaul workgroup has also started discussions on potential new study items to pursue for 2019.” An O-RAN industry event will kick off the MWC activities on Monday February 25th at 6:00pm, hosted by Deutsche Telekom on its stage in Hall 3. Following this event, O-RAN Alliance members will showcase six strategic proof-of-concepts across various member booths covering four key themes: intelligent RAN control, Open Interfaces, virtualization and white box. Chih-Lin I, China Mobile Chief Scientist an

Gain Therapeutics SA Announces Closing of EU 2.5 Million Series A Financing to Develop Novel Brain-Penetrant Non-Competitive Pharmacological Chaperones for Rare Lysosomal Storage Diseases and CNS Indications19.2.2019 07:30:00Pressemelding

GT Gain Therapeutics SA today announces that it has closed a €2.5 Million series A financing with VitaTech S.A. (€1.1Mio), Helsinn Investment Fund S.A. (€1Mio), and with existing investor TiVenture S.A. (€0.4). Gain Therapeutics SA is a private company, based in Lugano (Switzerland) and with a branch in Barcelona, that exclusively licensed an advanced computational technology (Site-directed Enzyme Enhancement Therapy, SEE-Tx®) used to identify next generation brain-penetrant non-competitive pharmacological chaperones. SEE-Tx® applicable to all diseases with a known genetic mutation in target proteins, allows the identification of brain-penetrant small molecules that provide a gain-of-function of misfolded proteins. Gain Therapeutics has already identified molecules for the treatment of a group of metabolic disorders called lysosomal storage disorders and some chronic degenerative diseases of the nervous system. Prof. Xavier Barril (CSO) commented: “The closing of this first part of ser

Australia Emerges as a Leading Innovator for Agriculture 4.019.2.2019 05:30:00Pressemelding

Australia’s long and distinguished history in agricultural research is cementing its position as a global hub for agriculture and food technology. Driven by a variety of climates and ecosystems, a stable and favourable business environment, and connectivity with the rapidly growing markets of Asia, Australia is capitalising on these advantages to become a centre for agtech and foodtech innovation. Australia for Agriculture 4.0, a new initiative by Austrade, the nation’s trade and investment promotion agency, will build on the country’s impressive record in agricultural innovation to facilitate foreign investment, exports and collaboration in both agtech and foodtech. The initiative aims to establish Australia as a global hub for agricultural and food innovation. It will showcase Australia’s agtech and foodtech capability, and highlight its unique technological advances, research excellence, strong record of innovation expertise, as well as the nation’s strong government support and est